Source: Eur Respir J 2011; 37: 690-711
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Leung C.C., Rieder H.L., Lange C., Yew W.W.. Treatment of latent infection with Mycobacterium tuberculosis: update 2010. Eur Respir J 2011; 37: 690-711

Member's Comments

No comment yet.

Related content which might interest you: Diagnosis and treatment of latent tuberculosis infection Source: Eur Respir Monogr 2018; 82: 381-398 Year: 2018 Management of latent Mycobacterium tuberculosis infection: WHO guidelines for countries with a low tuberculosis burden Source: International Congress 2016 – ERS publications: a focus on recent guidelines and task forces Year: 2016 Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries Source: Eur Respir J 2015; 46: 1563-1576 Year: 2015 Latent tuberculosis infection in a drug treatment centre Source: Eur Respir J 2002; 20: Suppl. 38, 366s Year: 2002 Clinical management of tuberculosis and HIV-1 co-infection Source: Eur Respir J 2010; 36: 1460-1481 Year: 2010 Diagnosis of latent tuberculosis infection Source: ERS Live 2007 Year: 2007 How should we treat latent tuberculosis infection? Source: Annual Congress 2003 - Latent tuberculosis infection - preventive approaches Year: 2003 Completion of treatment for latent tuberculosis infection Source: Annual Congress 2011 - Clinical tuberculosis Year: 2011 What is latent tuberculosis infection (LTBI)? Source: Annual Congress 2009 - Microbial colonisation or latency: a foot in the door to respiratory infections Year: 2009 Latent tuberculosis infection: a new paradigm Source: International Congress 2019 – State of the art session: Respiratory infections Year: 2019 LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement Source: Eur Respir J 2009; 33: 956-973 Year: 2009 Treatment failure in tuberculosis Source: Eur Respir J 2007; 29: 561-564 Year: 2007 Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection. Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Cost-effectiveness of interferon-γ release assay testing for the treatment of latent tuberculosis Source: Eur Respir J 2007; 30: 321-332 Year: 2007 Can we define latent tuberculosis infection? Source: Annual Congress 2003 - Latent tuberculosis infection - preventive approaches Year: 2003 Clinical and laboratory features of Mycobacterium avium complex infection in comparison with infection, caused by Mycobacterium tuberculosis, in HIV-infected patients Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Latent tuberculosis infection as a cause of tuberculosis disease Source: Eur Respir J 2003; 22: Suppl. 45, 157s Year: 2003 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2016; 47:1592-1594 Year: 2016 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2015; 46: 1397-1406 Year: 2015 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2016; 47:1594-1595 Year: 2016